The rich are pouring millions into life extension research – but does it have any ethical value?
- Written by: Julian Koplin, Lecturer in Bioethics, Monash University & Honorary fellow, Melbourne Law School, Monash University
Sam Altman, the chief executive of OpenAI, recently invested US$180 million into Retro Biosciences – a company seeking to extend human lifespans by ten healthy years.
One way it plans to achieve this is by “rejuvenating” blood. This idea is based on studies that found old mice showed signs of reversed ageing when given the blood...
